Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) Director Nancy Andrews sold 573 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the transaction, the director owned 1,438 shares in the company, valued at approximately $410,175.12. This represents a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Charles River Laboratories International Trading Up 1.0%
Shares of Charles River Laboratories International stock traded up $2.97 during trading hours on Thursday, hitting $292.97. The company’s stock had a trading volume of 1,059,340 shares, compared to its average volume of 927,192. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $299.32. The stock has a 50 day moving average of $230.73 and a 200 day moving average of $192.57. The company has a market capitalization of $13.99 billion, a PE ratio of -60.41, a price-to-earnings-growth ratio of 2.89 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter in the previous year, the business posted $3.12 EPS. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts predict that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
CRL has been the topic of a number of research reports. Royal Bank Of Canada boosted their price objective on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Mizuho set a $264.00 target price on Charles River Laboratories International in a research note on Monday, August 10th. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Morgan Stanley increased their target price on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $255.65.
Read Our Latest Stock Report on Charles River Laboratories International
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
